Shows / Making Medicine
Making Medicine
There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind…
Episodes
- Making Medicine
Inside the COINS Act: How Treasury’s China Rule Could Reshape Drug Development
Could Treasury’s proposed COINS Act rule make it harder for American patients to get promising new medicines? The proposed regulations would restrict a broad…
- Making Medicine
Myths vs. Facts: China, Biotech, and National Security
Are American biotech companies really sending $120 billion to China? And could restricting U.S. investment weaken America's position in the global biotech…
- Making Medicine
Biotech Boom, Drug Lag: Japan's Innovation Paradox
Japan has many of the ingredients of a world-class biotechnology ecosystem: leading scientific research, Nobel Prize-winning discoveries, and growing…
- Making Medicine
Ohio’s Biotech Boom: Gene Therapy, Investment & the Race with China
Ohio is emerging as a major U.S. life sciences hub, with growing investment in biotech, gene therapy, biomanufacturing and pharmaceutical innovation. But what…
- Making Medicine
AI in Drug Discovery: What Works, What’s Hype & What Comes Next
Artificial intelligence could transform drug discovery and biotech, but not necessarily in the ways the biggest AI predictions suggest. Where can AI actually…
- Making Medicine
China’s Biotech Rise: Clinical Trials, Drug Development & U.S. Competition
China’s biotech industry is expanding rapidly, reshaping clinical trials, drug development, licensing and the global competition for biomedical innovation…
- Making Medicine
Biotech’s Biggest Stories: Drug Pricing, Access & R&D
From billion-dollar drug development bets and looming patent cliffs to drug pricing, patient access and the future of U.S. clinical trials, some of the biggest…
- Making Medicine
9 Years vs. 13: The Problem With the Pill Penalty
Why does a small molecule medicine get nine years on the market before Medicare negotiation while a biologic gets 13? And what does that four-year difference…
- Making Medicine
Beyond the Sticker Price: The Real Economics of a $480,000 Cancer Drug
A new pancreatic cancer medicine could double survival time. Its annual list price? $480,000. That number is getting lots of attention, but the economics of…
- Making Medicine
Can AI Reinvent How America Makes Medicine? | How America Makes Medicine Ep. 6
🇺🇸 Artificial intelligence is reshaping biotech, drug discovery and medicine. But how much of the AI revolution is real, how much is hype, and what could it…
- Making Medicine
How Venture Capital Backed America's Biotech Engine | How America Makes Medicine Ep. 5
🇺🇸 Venture capital helped build America's biotech industry, but what happens when that capital stops flowing? In Episode 5 of the How America Makes Medicine…
- Making Medicine
Betting on Biotech: Dr. Jeremy Levin's Playbook | How America Makes Medicine Ep. 4
🇺🇸 Why does so much pharmaceutical innovation come from small biotech companies? And how do different parts of America's medicine ecosystem work together to…
- Making Medicine
The Relay Continues: Building Biotechs That Save Lives | How America Makes Medicine Ep. 3
🇺🇸 Every breakthrough medicine begins with a scientific discovery. But turning that discovery into a *treatment* that reaches patients*requires navigating one…
- Making Medicine
How Research Universities Power America’s Innovation Engine | How America Makes Medicine Ep. 2
🇺🇸 Every breakthrough medicine starts somewhere. Discover how research universities, NIH funding, and American innovation change lives. Every new medicine’s…
- Making Medicine
250 Years of American Pharmaceutical Innovation | How America Makes Medicine Ep. 1
🇺🇸 How America Makes Medicine begins with the remarkable story of 250 years of American pharmaceutical innovation. Welcome to How America Makes Medicine, a new…
- Making Medicine
FDA Leadership, China & The Future of American Biotech
🇺🇸 FDA leadership, China's growing role in clinical trials, NIH research, and biotechnology innovation are shaping the future of American medicine. This week…
- Making Medicine
Japan's Biotech Transformation: Drug Pricing, Clinical Trials & Global Investment
Japan's biotech industry is at a crossroads. Drug pricing reform, clinical trials, venture capital investment, and life sciences policy are all in flux as the…
- Making Medicine
Maria Thacker Goethe on Biotech Growth, Clinical Trials & US Competitiveness
Georgia's life sciences industry is growing fast. Biotech manufacturing, clinical trials, workforce development, and healthcare policy are reshaping America's…
- Making Medicine
Why FDA Instability is Driving Biotech Capital Abroad — What Investors Are Saying
FDA instability is reshaping biotech investment decisions in real time. Investors are recalibrating risk, pulling back, and even shifting capital abroad. In…
- Making Medicine
China’s Biotech Rise: What Tim Scott Saw Inside Shanghai
China's biotech innovation is accelerating. Clinical trials, NIH funding, and global competition are reshaping healthcare. Biocom’s President & CEO Tim Scott…
- Making Medicine
Patient Advocacy, FDA Partnerships & Building the Infrastructure of Drug Discovery
Rare diseases. Patient advocacy. Drug development. FDA partnerships. Clinical trials. Patient organizations have evolved into powerful engines of drug…
- Making Medicine
Healthcare Costs, PBMs & Why Manufacturers Oppose Drug Price Controls
Healthcare costs. PBM reform. Drug price controls. FDA stability. American manufacturing. This week on the Making Medicine Podcast, John Stanford sits down…
- Making Medicine
Rep. Scott Peters on the Pill Penalty, PBMs, China & America’s Biotech Future
China and biotech competition. Drug pricing reform. The FDA. PBMs. America’s innovation economy. This week on the Making Medicine Podcast, John Stanford sits…
- Making Medicine
The FDA Decoded: Roles, Responsibilities & What They Mean for Drug Development
What does the FDA actually look like on the inside — and why does its structure matter for drug approvals, rare disease therapies, and biotech investment? This…
- Making Medicine
FDA Leadership After Marty Makary: What Biotech Needs Next
FDA instability. AI in clinical trials. China overtaking the United States in biotech development. Following news that Marty Makary has stepped down as FDA…
- Making Medicine
FDA Approvals Corner, Immigration Warnings & Germany's MFN Complication | Making Medicine Headlines
Gene therapy breakthroughs. The first oral GLP-1 pill. A troubling signal for scientific talent. And a German pricing move that could quietly reshape global…
- Making Medicine
Senator Todd Young on China, FDA Reform, and Why Biotech Is National Security
Biotech is no longer just about medicine. It is now a frontline issue in national security, global competition, and economic independence. In this episode of…
- Making Medicine
FDA Instability Is Changing Biotech Investment—What Investors Are Saying
FDA instability is reshaping biotech investment decisions in real time. Investors are recalibrating risk, pulling back, and even shifting capital abroad. In…
- Making Medicine
FDA Signals Are Breaking Biotech | Collapse, Breakthrough, and What Congress Does Next
FDA signals are starting to break down, and biotech is feeling it. One company is collapsing while another is breaking through. As lawmakers return to…
- Making Medicine
Tariffs, MFN & FDA Delays: Why Biotech Is at Risk
Tariffs, MFN pricing, and FDA delays are colliding, and small biotech is paying the price. One company already collapsed. More could follow. In this episode…
- Making Medicine
The China Biotech Threat Is Already Here | John Gutierrez on Capitol Hill, Drug Pricing & FDA
Last week, seven leading life sciences investors went to Washington. They met with the National Security Commission on Emerging Biotechnology, walked the halls…
- Making Medicine
Biotech, National Security, and Global Competition | Dr. Rozo (NSCEB) | JPM Re-Air
In this special re-air of the Making Medicine Podcast, we revisit a timely conversation with Dr. Michelle Rozo of the National Security Commission on Emerging…
- Making Medicine
Solving Japan's Drug Lag: Why PM Takaichi Must Agree to a Fair U.S. Pricing Deal
With Japanese Prime Minister Sanae Takaichi meeting President Trump this week, we are re-airing our special episode from Tokyo. We explore why the U.S…
- Making Medicine
Regulatory Risk: How FDA Instability Is Threatening America's Biotech Investment Edge
The FDA is being asked to keep pace with today's rapid scientific advancements amid ongoing resource constraints. In this episode, we unpack why regulatory…
- Making Medicine
China Just Passed the U.S. in Drug Clinical Trials
China has now overtaken the United States in new drug clinical trials. At the same time regulatory uncertainty and funding lapses are raising new questions…
- Making Medicine
Why 95% of Rare Diseases Still Have No Treatment
About 90–95% of rare diseases still lack an FDA-approved treatment, underscoring the urgency for continued innovation on behalf of the estimated 30 million…
- Making Medicine
FDA Chaos and Foreign Price Controls Are Collapsing American Innovation
FDA reversals and price controls are handing biotech dominance to China. We expose the national security crisis in drug development. The FDA is facing a crisis…
- Making Medicine
TrumpRx Explained: Cash Markets, MFN, and What This Moment Means for Drug Pricing
TrumpRx has quickly become part of the broader drug pricing conversation, not as a new insurance program or pharmacy, but as a government website highlighting…
- Making Medicine
Speed, Scrutiny, and Spending: How Washington Is Reshaping the Future of Medicine
Washington is navigating a period of significant change in health policy, with implications for how new medicines are developed, reviewed, and paid for. In…
- Making Medicine
Live From JPM 2026: Is This the End of American Biotech Leadership?
The race is being won by someone else. While the headlines focus on the prestige of JPM 2026, a much quieter and more dangerous shift is happening behind the…
- Making Medicine
How Global Competition and U.S. Policy Choices Are Reshaping Biotech | Live at JPM 2026 (Part 2)
Is the U.S. at risk of losing its edge in biotech innovation? Filmed live at JPM 2026, host John Stanford sits down with industry leaders who are deep in the…
- Making Medicine
Innovation at a Crossroads | Live at JPM 2026 (Part 1)
Filmed live at the JPMorgan Healthcare Conference 2026, this episode of the Making Medicine Podcast examines how global power shifts are reshaping the…
- Making Medicine
CMS Drug Pricing Proposals and What JPM 2026 Signals
In this episode of the Making Medicine Podcast, John Stanford previews new CMS drug pricing proposals and explains how they could shape biotech investment and…
- Making Medicine
How Policy Shapes the Future of Life Sciences
In this New Year episode of the Making Medicine Podcast, we revisit a full-length conversation with U.S. Senator Thom Tillis of North Carolina, focused on the…
- Making Medicine
Year in Review: Biotech Innovation, Policy, and Global Competition
In this special holiday episode, the Making Medicine Podcast looks back at standout conversations since the show’s July relaunch, covering biotech innovation…
- Making Medicine
Biotech in 2025: Investment Trends, Congress, and Approvals
In this year-in-review episode, we break down key biotech investment trends from 2025, major policy developments in Congress, and what they mean for innovation…
- Making Medicine
What the NDAA Means for the Future of Biotech
This episode breaks down how Congress is turning biotechnology into a core national security priority. John Stanford explains the biggest shifts in the 2025…
- Making Medicine
Inside Congress: Senator Thom Tillis on Drug Pricing, IP, and the Future of Innovation
In this episode of Making Medicine, host John Stanford sits down with Senator Thom Tillis, the first sitting U.S. Senator to join the show. Tillis opens up…
- Making Medicine
Making Medicine ft. Daphne Zohar. Biotech Flywheels, Policy Risks, and the Future of Innovation
In this episode of the Making Medicine Podcast, John Stanford sits down with Daphne Zohar, Founder, CEO, and Board Member of Seaport Therapeutics to explore…
- Making Medicine
Japan’s Life Sciences State of Play: The Takeaways You Can’t Miss
In this special Tokyo edition of the Making Medicine Podcast, John Stanford hosts a powerhouse panel of biotech investors, founders, and industry leaders to…
- Making Medicine
Inside Biotech Leadership: Bill Newell on Innovation, Capital, and Policy at Sutro Biopharma
Former Sutro Biopharma CEO Bill Newell joins host John Stanford to discuss the realities of leading a biotech company through economic uncertainty, long…
- Making Medicine
U.S. Biomanufacturing Surge, Arena BioWorks Fallout & GLP-1 Rumors | Making Medicine Podcast
In this episode, John Stanford breaks down the surge in U.S. biomanufacturing investments, including Virginia’s new $500B hub, and what it means for the…
- Making Medicine
Is the U.S. Losing Its Biotech Edge to China? Senate Hearing & Innovation Outlook
In this episode of Making Medicine, host John Stanford unpacks the Senate HELP Committee hearing on “The Future of Biotech.” From China’s accelerating…
- Making Medicine
FDA Vouchers, Orphan Cures & IP with Joshua Kresh
In this week’s episode, John breaks down the White House headlines, the FDA’s new wave of priority review vouchers, and September approvals, then celebrates…
- Making Medicine
Shutdown Fallout, MFN Deals & BIOSECURE Returns
In this week’s episode, John Stanford breaks down Day 15 of the federal shutdown’s impact on health agencies, major pullbacks in cell & gene therapy, and the…
- Making Medicine
Boston Biotech Pulse: Shutdowns, Pfizer Deal, and the Future of Innovation
In this week’s episode, John Stanford reports from Boston - the beating heart of global biotech - with insights from investors, scientists, and executives…
- Making Medicine
Government Shutdown, SBIR Expiration, and Trump’s Pharma Moves | Making Medicine Podcast
This week, John Stanford breaks down the government shutdown and its impact on FDA, NIH, and biotech innovation. He also covers the surprising lapse of the…
- Making Medicine
China’s Biotech Surge, GLP-1 Prices, & MFN Deadline | Press Pass with Max Bayer
In this week’s episode, John Stanford breaks down the White House autism event, the debate over shifting SEC reports to twice-yearly, and how MFN pressure is…
- Making Medicine
UK Pharma Challenges, DTC Ads Debate & 5 New FDA Approvals | Making Medicine
This week, John Stanford dives into the UK’s pharmaceutical challenges, including ABPI’s warning about declining competitiveness and major companies pausing…
- Making Medicine
Ending the Pill Penalty on 9/13, Tariffs & FDA Rare Disease Guidance | Making Medicine
In this week’s episode, John Stanford reflects on Incubate’s own holiday, September 13th (9/13), and the ongoing fight to end the pill penalty through the EPIC…